1 Though the ineffective hematopoiesis may be due to excessive apoptosis in MDS, 2 the precise mechanism is unknown. Chemokines are small cytokines that are important as intermediates in the inflammatory response, and are regulatory proteins for the recruitment and trafficking of leukocytes. 3 Recently, stromal cell-derived factor-1 (SDF-1) was identified as the predominant chemotactic factor produced by bone marrow cells. 4 The SDF-1 and its receptor CXCR4 are involved in the mobilizing and trafficking of hematopoietic progenitor cells. 5 SDF-1 also enhances survival/antiapoptosis of hematopoietic progenitor cells, in vitro as well as in vivo, 6 suggesting that the SDF-1/CXCR4 system plays an important role in hematopoietic cell regulation. Therefore, we investigated the The apoptosis of CD34 + progenitor cells was qualified by the Annexin V method. CXCR4 expression in mean fluorescence intensities (MFI) on CD34 + progenitor cells was given after correction with reference to the mouse IgG control. SDF-1-induced chemotaxis was expressed as % input cells. SDF-1 concentration in BM plasma was measured by ELISA.
correlation between apoptosis and the SDF-1/CXCR4 system in CD34 þ progenitor cells from patients with MDS. Permission for this study was obtained from the Institutional Review Board. After informed consent was given, bone marrow (BM) mononuclear cells were obtained from 19 patients with newly diagnosed low-risk MDS (low or intermediate-1 International Prognostic Scoring System 7 category) and from 10 age/ gender-matched healthy volunteers. According to the French, American, and British (FAB) morphologic guidelines for MDS classification, 12 patients had refractory anemia (RA), three had RA with ringed sideroblast (RARS), and four had RA with excess blast (RAEB) with less than 10% blast in the bone marrow (Table 1) . Cytopenia was defined as a hemoglobin level of less than 10 g/dl, an absolute neutrophil count of less than 1 500/ml, and a platelet count of less than 100 000/ml. All patients with MDS demonstrated cytopenia of more than two lineages. All BM aspirates were taken at the time of initial presentation before the start of therapy. Patients with hypocellular bone marrow were excluded from this study. All samples were analyzed within 4 h of aspiration.
BM CD34
þ progenitor cells were isolated with immunomagnetic microbeads (DYNAL CD34 Progenitor Cell Selection System, DYNAL, Oslo, Norway). Using the Annexin V method, the apoptosis of CD34 þ progenitor cells from patients with lowrisk MDS (mean values: 33.6% (8.6-74.1%)) was found to be greater than that from healthy volunteers (mean values: 5.6% (3.1-8.7%), Po0.05), which is consistent with the previous report 8 ( Table 1 ). Flow cytometry indicated that no significant differences in CXCR4 expression on CD34 þ progenitor cells were observed between patients with MDS (mean values of MFI: 17.6) and healthy volunteers (mean value of MFI: 16.1) (Table 1) . However, the chemotaxis assay demonstrated that CD34 þ progenitor cells from patients with MDS showed marginal chemotactic response to SDF-1 (100 ng/ml) (mean values of % input: 4.5% (2-9%)), whereas those from healthy volunteers actively migrated (mean value of % input: 19.6% (11-31%), Po0.0001) ( Table 1 and Figure 1a ). There was no significant difference in chemotactic response to SDF-1 among MDS subtypes (data not shown). These findings suggest that CXCR4 expressed on CD34 þ progenitor cells from patients with MDS do not respond to SDF-1 effectively. þ progenitor cells from patients with MDS. The x-axis and the y-axis represent % apoptosis and the SDF-1-induced (100 ng/ml) chemotaxis (% input) of the cells, respectively. Continuous variables were compared by using Student's t-test. Correlation was determined with a simple regression analysis.
Figure 2
Correlation between apoptosis in CD34 þ progenitor cells and SDF-1 levels in BM plasma. þ progenitor cells and SDF-1 levels in BM plasma from patients with MDS. The x-axis and the y-axis represent % apoptosis and the SDF-1 levels in BM plasma, respectively. Continuous variables were compared by using Student's t-test. Correlation was determined with a simple regression analysis.
Next, we investigated the correlation between apoptosis and the SDF-1-induced chemotaxis in CD34 þ progenitor cells from patients with MDS (Figure 1b) . The results showed that a negative correlation (r ¼ À0.49, Po0.05) was found between apoptosis and the chemotactic response to SDF-1 (Figure 1b) . These data suggest that the lack of chemotactic response to SDF-1 in CD34 þ progenitor cells may be associated with apoptosis in low-risk MDS patients.
Furthermore, we measured SDF-1 levels in BM plasma from patients with MDS and healthy volunteers by enzyme-linked immunosorbent assay (ELISA) using Quantikine s , human SDF1a immunoassay (R&D systems, Minneapolis, MN, USA) ( Table 1 and Figure 2) . SDF-1 levels in BM plasma from MDS patients (mean values: 970.4 pg/ml (669.6-1344.7 pg/ml)) were detected to be more than that from healthy volunteers (mean values: 634.6 pg/ml (398.4-830.3 pg/ml), Po0.0001) ( Table 1 and Figure 2a) . Surprisingly, a significant positive correlation (r ¼ 0.53, Po0.05) was found between apoptosis and the SDF-1 levels (Figure 2b ). These observations suggest that SDF-1 levels in BM plasma may be an important marker for apoptosis in CD34 þ progenitor cells in low-risk MDS patients. In conclusion, we have described a potential role of the SDF-1/CXCR4 system in compromising hematopoiesis in low-risk MDS.
Further studies are required to analyze the detailed mechanism of the unresponsiveness to SDF-1 in CD34 þ progenitor cells in low-risk MDS patients, and to examine how the constitutive production of SDF-1 in BM may be regulated by the chemotactic response in CD34 þ progenitor cells in MDS patients. It would be interesting to possible therapeutic application of the SDF-1/CXCR4 system to render hematopoiesis ineffective in low-risk MDS.
